ELCC21 ：Proffered Paper session

主要就三个，但视频卡得一比，先找了点图凑数

Date Thu, 25.03.2021 

Time 14:35 - 15:55

96O - Camrelizumab or placebo plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-sq): A randomized, double-blind, multicenter, phase III trial

Totally, 389 pts (camrelizumab plus chemo, n = 193; placebo plus chemo, n = 196) were included. As of Nov. 06, 2020, pts treated with camrelizumab plus chemo were associated with significantly prolonged IRC-assessed PFS versus placebo plus chemo (median, 8.5 [95% CI 6.9–10.4] vs 4.9 [95% CI 4.2–5.5] months; HR, 0.37 [95% CI 0.29–0.47], one-sided P < 0.0001), with benefit observed in pts with both PD-L1 TPS <1% (HR, 0.49 [95% CI 0.35–0.68]) and ≥1% (HR, 0.34 [95% CI 0.24–0.49]). There was also significant improvement in OS for the camrelizumab plus chemo group (median, NR [18.4–NR] vs 14.5 [95% CI 13.2–16.6] months; HR, 0.55 [95% CI 0.40–0.75], one-sided P < 0.0001). Consistently, confirmed ORR (64.8% [95% CI 57.6%–71.5%] vs 36.7% [95% CI 30.0%–43.9%], P < 0.0001) and DoR (median, 13.1 [95% CI 9.3–15.7] vs 4.4 [95% CI 4.2–4.9] months) per IRC favored the camrelizumab plus chemo group. Grade ≥3 treatment-related adverse events occurred in 73.6% of pts in the camrelizumab plus chemo group and 71.9% in the placebo plus chemo group, with no unexpected adverse effects.

97O - First-Line Pembrolizumab Plus Chemotherapy for Patients With Advanced Squamous NSCLC: 3-Year Follow-up From KEYNOTE-407

As of Sep 30, 2020, median time from randomization to data cutoff was 40.1 (range, 33.1–49.4) mo; 117 (41.6%) pts crossed over from the placebo + chemo group to receive pembro monotherapy. Median OS in the pembro + chemo group was 17.2 vs 11.6 mo for placebo + chemo; HR 0.71 (95% CI, 0.59–0.86). 3-year OS rate was 29.7% vs 18.2%, respectively. Median PFS2 was 13.8 vs 9.1 mo, respectively; HR 0.59 (95% CI, 0.49–0.71; Table). Grade 3–5 AEs occurred in 74.8% of pts in the pembro + chemo group and 70.0% in the placebo + chemo group. Among 55 pts who completed 35 cycles of pembro, ORR was 92.7% (5 CR, 46 PR) and 4 pts (7.3%) had SD. 51 pts (92.7%) were alive, and 1-year OS and PFS after completion of 35 cycles were 96.0% and 82.6%. 7 pts had initiated a second course of pembro at data cutoff.

98O - First-line nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles chemotherapy (chemo) vs 4 cycles chemo in advanced non-small cell lung cancer (aNSCLC): association of blood and tissue tumor mutational burden (TMB) with efficacy in CheckMate 9LA

Of 711 randomized pts with available TMB data at DBL, 64% had evaluable tTMB and 73% had evaluable bTMB. Baseline characteristics were generally well balanced between all randomized, TMB-evaluable and non-evaluable, as well as TMB-high and TMB-low subgroups (both bTMB and tTMB). Overall, clinical benefit (OS, PFS, ORR) was observed with NIVO + IPI + chemo vs chemo in both TMB-high and TMB-low subgroups (Table). The OS benefit with NIVO + IPI + chemo vs chemo was similar between tTMB ≥10 and <10 mut/Mb, and between bTMB ≥16 and <16 mut/Mb subgroups; a numerically higher OS benefit was seen in bTMB ≥20 vs <20 mut/Mb subgroups. For PFS and ORR, the magnitude of benefit was higher in TMB-high versus TMB-low subgroups for both tTMB and bTMB.

其实今天的新闻是

回顾之前：BMS-986106+Nivo用于PD-1/-L1后进展的MEL，可以看出基疗效与LAG-3表达相关而与PD-L1+ 表达无关，所以主要是LAG-3+阳性的这部分患者贡献，另外也说明MHC II至少在黑色素瘤中是LAG-3的主要配体

然后回顾下CM-067 O+Y vs O vs Y in 1L MEL regardless of BRAF status

  • ORR 58% vs 45% vs 19%

  • PFS 11.5 mo vs 6.9 mo vs 2.9mo【O+Y vs Y HR 0.42，O vs Y HR 0.53】

  • OS NR(>60mo) vs 36.9mo vs 19.9mo【O+Y vs Y HR 0.52，O vs Y HR 0.63】

不过Relatilmab的特点就是安全

赞 (0)

相关推荐